NervGen Pharma to Present at Upcoming Investor Conferences
NervGen Pharma to Present at Upcoming Investor Conferences
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that members of its management will be presenting at two upcoming investor conferences:
溫哥華，不列顛哥倫比亞省-(Newsfile Corp.-2023年6月20日)-NervGen製藥公司(TSXV：NGEN)(OTCQX：NGENF)(“NervGen”或“公司”)是一家致力於開發治療神經系統損傷的創新解決方案的臨床階段生物技術公司，該公司今天宣佈，其管理層成員將在即將舉行的兩個投資者會議上發言：
- Mike Kelly, President & CEO, will present at the Life Science Investors Forum, hosted by OTC Markets Group on VirtualInvestorConferences.com, on June 22, 2023 at 11:30am Eastern Daylight Time (EDT), and members of management will be available for one-on-one investor meetings on June 26, 2023.
LINK:
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
- 總裁首席執行官Mike·凱利將出席2023年6月22日東部夏令時間上午11：30由場外市場集團在VirtualInvestorConferences.com上舉辦的生命科學投資者論壇，管理層成員將於2023年6月26日參加一對一的投資者會議。
鏈接：
這將是一個現場直播的互動在線活動，投資者被邀請即時向公司提問。如果與會者不能在會議當天現場直播，活動結束後還將提供存檔的網路直播。
- Dr. Dan Mikol, Chief Medical Officer, will present at the 1st Annual Spinal Cord Injury Investor Symposium, presented by Lineage Cell Therapeutics, Inc. and Christopher & Dana Reeve Foundation, on June 29, 2023 at 2:30pm Pacific Daylight Time (PDT), at the Sanford Consortium for Regenerative Medicine in La Jolla, CA.
LINK:
Dr. Mikol will provide an overview of the results from preclinical studies and the Phase 1 trial for NervGen's proprietary lead drug candidate, NVG-291, as well as the design of the upcoming Phase 1b/2a proof of concept clinical trial in individuals with spinal cord injury.
- 首席醫療官Dan Mikol博士將出席1ST一年一度的脊髓損傷投資者研討會，由Lineage Cell Treateutics，Inc.和Christopher&Dana Reve基金會主辦，於2023年6月29日太平洋夏令時間下午2：30在加利福尼亞州拉霍亞的Sanford再生醫學聯盟舉行。
鏈接：
米科爾博士將概述NervGen的專利候選主藥NVG-291的臨床前研究和第一階段試驗的結果，以及即將在脊髓損傷患者中進行的1b/2a階段概念驗證臨床試驗的設計。
About NVG-291
NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair. NVG-291 is derived from the intracellular domain of the receptor type protein tyrosine phosphatase sigma (PTPσ). NVG-291-R, a rodent analog of NVG-291, has been shown to promote nervous system repair and functional recovery in animal models of spinal cord injury, peripheral nerve injury, multiple sclerosis and stroke, through enhanced plasticity, axonal regeneration, and remyelination.
關於NVG-291
NervGen擁有NVG-291的全球獨家權利，NVG-291是一種幹擾神經系統修復的一流治療多肽靶向機制。NVG-291來源於受體類型蛋白酪氨酸磷酸酵素Sigma(PtPσ)的胞內結構域。NVG-291-R是NVG-291的齧齒動物類似物，已被證明通過增強可塑性、軸突再生和髓鞘再生，促進脊髓損傷、周圍神經損傷、多發性硬化症和中風動物模型的神經系統修復和功能恢復。
About NervGen
NervGen (TSXV: NGEN) (OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen's lead drug candidate, NVG-291, is currently planned to be evaluated in a Phase 1b/2a clinical trial. The Company's initial target indication is spinal cord injury. For more information, go to .
關於NervGen
NervGen(多倫多證券交易所股票代碼：NGENF)是一家臨床階段的生物技術公司，致力於開發創新的治療方法，使神經系統在受損後能夠自我修復，無論是由於受傷還是疾病。NervGen的主要候選藥物NVG-291目前計劃在1b/2a期臨床試驗中進行評估。該公司最初的目標適應症是脊髓損傷。有關更多資訊，請訪問。
For further information, please contact:
如需更多資訊，請聯繫：
Huitt Tracey, Corporate Communications
htracey@nervgen.com
604.537.2094
Huitt Tracey，企業傳播部
郵箱：htrey@nerggen.com
604.537.2094
Nancy Thompson, Vorticom Public Relations
nancyt@vorticom.com
212.532.2208
南希·湯普森，Vorticom公共關係部
郵箱：nancyt@vorticom.com
212.532.2208
Follow NervGen on Twitter, LinkedIn, and Facebook for the latest news on the Company.
沿著NervGen行駛推特，LinkedIn，以及Facebook獲取有關該公司的最新消息。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所創業板交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
Cautionary Note Regarding Forward-Looking Statements
有關前瞻性陳述的注意事項
This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities legislation. Such forward-looking statements and information herein include, but are not limited to, the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the subject matter to be presented at the upcoming investor conferences; the objectives, timing and study design of the clinical development of NVG-291; the belief that modulating the activity of PTPσ is a promising target for reducing the clinical effects of nervous system damage through multiple mechanisms; and the creation of innovative treatments of nervous system damage due to trauma or disease.
本新聞稿可能包含適用於加拿大和美國證券法的“前瞻性資訊”和“前瞻性陳述”。本文中的前瞻性陳述和資訊包括但不限於，公司當前和未來的計劃、預期和意圖、結果、活動水準、業績、目標或成就，或任何其他未來事件或發展構成前瞻性陳述，“可能”、“將”、“將”、“應該”、“可能”、“預期”、“計劃”、“打算”、“趨勢”、“指示”、“預期”、“相信”、“估計”、“預測”等辭彙構成前瞻性陳述。“可能”或“潛在”，或這些詞語或其他類似詞語或短語的否定或其他變體，旨在識別前瞻性陳述。前瞻性表述包括但不限於：將要在即將召開的投資者大會上提出的主題；NVG-291臨床開發的目標、時機和研究設計；認為調節PTPσ的活性是通過多種機制減少神經系統損害的臨床影響的有希望的目標；以及創建針對創傷或疾病造成的神經系統損害的創新治療方法。
Forward-looking statements are based on estimates and assumptions made by the Company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, the Company has relied on various assumptions, including, but not limited to: the Company's ability to manage the effects of the COVID-19 pandemic; the accuracy of the Company's financial projections; the Company obtaining positive results in its clinical and other trials; the Company obtaining necessary regulatory approvals; and general business, market and economic conditions.
前瞻性陳述基於本公司根據管理層的經驗和對歷史趨勢、當前狀況和預期未來發展的看法以及我們認為在當時情況下適當和合理的其他因素而作出的估計和假設。在做出前瞻性陳述時，公司依賴於各種假設，包括但不限於：公司管理新冠肺炎疫情影響的能力；公司財務預測的準確性；公司在臨床和其他試驗中取得積極結果；公司獲得必要的監管批准；以及一般商業、市場和經濟狀況。
Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, the impact of the COVID-19 pandemic, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the Company's Annual Information Form, Short Form Base Shelf Prospectus, financial statements and Management Discussion and Analysis which can be found on SEDAR.com. All clinical development plans are subject to additional funding.
許多因素可能會導致我們的實際結果、活動水準、業績或成就或未來的事件或發展與前瞻性陳述中明示或暗示的內容大不相同，包括但不限於收入缺乏、資金不足、新冠肺炎疫情的影響、對關鍵人員的依賴、臨床開發過程的不確定性、競爭以及公司年度資訊表格、簡短基礎架子簡介、財務報表以及管理討論與分析中“風險因素”部分闡述的其他因素。這些因素可在SEDAR.com上找到。所有臨床開發計劃都需要額外的資金。
Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and we have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
讀者不應過分依賴本新聞稿中的前瞻性陳述。此外，除非另有說明，本新聞稿中包含的前瞻性陳述都是截至本新聞稿發佈之日作出的，我們無意也沒有義務更新或修改任何前瞻性陳述，無論是由於新資訊、未來事件還是其他原因，除非適用法律要求。本新聞稿中包含的前瞻性陳述明確地受到本警示性聲明的限制。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。